Shanghai Wanxing Bio-Pharmaceutical Co. Ltd. Report issue

For profit Phase 1
Founded: Shanghai China (1996)
Status: Defunct (2016)

Organization Overview

First Clinical Trial
2006
NCT00284973
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2006

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 1 Trials (2)

montanide isa 720 (1 trial)

plasmodium falciparum chimeric prot. 2.9 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Malaria (Phase 1)

Malaria, Falciparum (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 2